New hope for Hard-to-Treat myeloma: targeted drug shows promise

NCT ID NCT03525678

Completed Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 2 trial tested a drug called belantamab mafodotin in 221 people with multiple myeloma that had not responded to at least three prior treatments. The drug is an antibody-drug conjugate that delivers a toxin directly to cancer cells. Participants received one of two doses intravenously every three weeks. The main goal was to see how many patients had their cancer shrink or disappear.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

belantamab mafodotin

What this could lead to

If successful, this could provide a new treatment option for patients with multiple myeloma who have run out of effective therapies.

What could go wrong

This is a phase 2 trial with a relatively small number of participants, so results may not confirm broader effectiveness. The drug can cause side effects like eye problems and low blood counts.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Show contact details

Locations

GSK Investigational Site

New Haven, Connecticut, 06510, United States
GSK Investigational Site

Atlanta, Georgia, 30322, United States
GSK Investigational Site

Atlanta, Georgia, 30342, United States
GSK Investigational Site

Chicago, Illinois, 60612, United States
GSK Investigational Site

Chicago, Illinois, 60637, United States
GSK Investigational Site

Indianapolis, Indiana, 46202, United States
GSK Investigational Site

Fairway, Kansas, 66205, United States
GSK Investigational Site

Baton Rouge, Louisiana, 70121, United States
GSK Investigational Site

Baltimore, Maryland, 21201, United States
GSK Investigational Site

Boston, Massachusetts, 02215, United States
GSK Investigational Site

Rochester, Minnesota, 55905, United States
GSK Investigational Site

New York, New York, 10029, United States
GSK Investigational Site

New York, New York, 10065, United States
GSK Investigational Site

Charlotte, North Carolina, 28204, United States
GSK Investigational Site

Columbus, Ohio, 43210, United States
GSK Investigational Site

Philadelphia, Pennsylvania, 19104, United States
GSK Investigational Site

Nashville, Tennessee, 37232, United States
GSK Investigational Site

Houston, Texas, 77030, United States
GSK Investigational Site

Salt Lake City, Utah, 84112, United States
GSK Investigational Site

Seattle, Washington, 98109, United States
GSK Investigational Site

Madison, Wisconsin, 53792, United States
GSK Investigational Site

Woodville, South Australia, 5011, Australia
GSK Investigational Site

Fitzroy, Victoria, 3065, Australia
GSK Investigational Site

Melbourne, Victoria, 3004, Australia
GSK Investigational Site

Calgary, Alberta, T2N 4N2, Canada
GSK Investigational Site

Winnipeg, Manitoba, R3E 0V9, Canada
GSK Investigational Site

Toronto, Ontario, M5G 2M9, Canada
GSK Investigational Site

Lille, 59037, France
GSK Investigational Site

Nantes, 44093, France
GSK Investigational Site

Paris, 75010, France
GSK Investigational Site

Pessac, 33600, France
GSK Investigational Site

Pierre-Bénite, 69495, France
GSK Investigational Site

Toulouse, 31059, France
GSK Investigational Site

Dresden, 01307, Germany
GSK Investigational Site

Hanover, 30625, Germany
GSK Investigational Site

Koblenz, 56068, Germany
GSK Investigational Site

Schwerin, 19049, Germany
GSK Investigational Site

Tübingen, 72076, Germany
GSK Investigational Site

Würzburg, 97080, Germany
GSK Investigational Site

Aviano PN, 33081, Italy
GSK Investigational Site

Parma, 43126, Italy
GSK Investigational Site

Rionero in Vulture PZ, 85028, Italy
GSK Investigational Site

Torino, 10126, Italy
GSK Investigational Site

Badalona, 08916, Spain
GSK Investigational Site

Barcelona, 08036, Spain
GSK Investigational Site

Granada, 18014, Spain
GSK Investigational Site

Madrid, 28041, Spain
GSK Investigational Site

Madrid, 28223, Spain
GSK Investigational Site

Murcia, 30008, Spain
GSK Investigational Site

PamplonaNavarra, 31008, Spain
GSK Investigational Site

Salamanca, 37007, Spain
GSK Investigational Site

Valencia, 46017, Spain
GSK Investigational Site

Birmingham, B9 5SS, United Kingdom
GSK Investigational Site

Bournemouth, BH7 7DW, United Kingdom
GSK Investigational Site

London, NW1 2BU, United Kingdom
GSK Investigational Site

Nottingham, NG5 1PB, United Kingdom
GSK Investigational Site

Oxford, OX3 7LE, United Kingdom
GSK Investigational Site

Stoke-on-Trent, ST4 6QG, United Kingdom
GSK Investigational Site

Sutton, SM2 5PT, United Kingdom